Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for
 intravenous use in clinical settings of the following diseases:

 1. T-cell acute lymphocytic leukemia (T-ALL)

 2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological
 disorder, hypotension, and blood disorder and their details" are to be investigated as
 an item of particular concern. In addition, subject outcome (alive or dead) at one year
 after the start of treatment will also be investigated.
Inclusion Criteria:

 -  Diagnosis of T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic
 lymphoma (T-LBL)

 Exclusion Criteria:

 -  Subjects with hypersensitivity to nelarabine